6-K: Transaction notification
6-K: Transaction notification
6-K: Gsk Delivers Strong 2024 Performance with Further Improvement to Long-Term Growth Outlook
6-K: Total Voting Rights and Capital
6-K: Depemokimab Applications Accepted for Review in China and Japan for Asthma with Type 2 Inflammation and Crswnp
6-K: Depemokimab Accepted for Review by the European Medicines Agency for Use in Asthma with Type 2 Inflammation and Crswnp
6-K: Gsk's Shingrix New Prefilled Syringe Presentation Accepted for Review by European Medicines Agency
6-K: European Commission Expands Jemperli (Dostarlimab) Plus Chemotherapy Approval to All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Transaction Notification
6-K: Transaction Notification
6-K: Transaction Notification
6-K: Gsk Enters Agreement to Acquire Idrx, Inc.
6-K: Gsk's Shingrix New Prefilled Syringe Presentation Accepted for Review by Us Fda
6-K: Gsk's B7-H3-Targeted Antibody-Drug Conjugate, Gsk'227, Receives Us Fda Breakthrough Therapy Designation in Late-Line Relapsed or Refractory Osteosarcoma
6-K: Gsk's Nucala (Mepolizumab) Approved in China for Treatment of Adults with Chronic Rhinosinusitis with Nasal Polyps
6-K: Total Voting Rights and Capital
6-K: Transaction Notification
6-K: Block Listing Application
6-K: Gsk Announces First Trial Met Its Primary Endpoint of Progression Free Survival in First Line Advanced Ovarian Cancer